Femasys (NASDAQ:FEMY) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Femasys (NASDAQ:FEMY) from a hold rating to a sell rating in a report released on Saturday.

FEMY has been the topic of a number of other reports. Lake Street Capital reduced their target price on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, August 18th. Maxim Group dropped their price target on shares of Femasys to $10.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Weiss Ratings downgraded shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

Femasys Stock Up 0.7%

Shares of NASDAQ:FEMY opened at $2.98 on Friday. The company has a quick ratio of 0.55, a current ratio of 2.14 and a debt-to-equity ratio of 0.89. The business has a fifty day moving average of $3.34 and a two-hundred day moving average of $6.92. The stock has a market cap of $24.96 million, a P/E ratio of -0.84 and a beta of -2.08. Femasys has a 52-week low of $2.02 and a 52-week high of $22.20.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings results on Friday, August 14th. The company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.31) by ($0.02). The company had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.73 million. Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%.

Insider Activity

In related news, CFO Dov Elefant purchased 15,625 shares of the company’s stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the chief financial officer directly owned 15,625 shares in the company, valued at approximately $50,000. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Kathy Lee-Sepsick purchased 15,625 shares of the company’s stock in a transaction on Friday, August 7th. The shares were bought at an average price of $3.20 per share, with a total value of $50,000.00. Following the completion of the transaction, the chief executive officer owned 15,625 shares of the company’s stock, valued at approximately $50,000. The trade was a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 38,750 shares of company stock valued at $124,000. 7.75% of the stock is currently owned by insiders.

Institutional Trading of Femasys

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FEMY. Geode Capital Management LLC boosted its position in shares of Femasys by 50.8% during the fourth quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock worth $224,000 after buying an additional 131,052 shares during the period. Banco BTG Pactual S.A. purchased a new stake in shares of Femasys in the 4th quarter valued at $88,000. Jane Street Group LLC acquired a new position in Femasys during the 4th quarter worth about $62,000. State Street Corp boosted its holdings in Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after acquiring an additional 24,500 shares during the period. Finally, Cetera Investment Advisers purchased a new position in Femasys during the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.